Listen now | The legendary founder behind MongoDB, Business Insider, and Gilt on how psychedelics are driving breakthrough results in treating depression—and how AI will uncover materials humans never imagined.
͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­
Forwarded this email? Subscribe here for more
 
The Generalist
The Generalist
Why Psychedelics Might Be the…
0:001:08:10
 
Listen now
 

Why Psychedelics Might Be the Breakthrough that PTSD Patients Need | Kevin Ryan (The Godfather of NYC Tech)

The legendary founder behind MongoDB, Business Insider, and Gilt on how psychedelics are driving breakthrough results in treating depression—and how AI will uncover materials humans never imagined.

Mario Gabriele
Oct 28
 
READ IN APP
 

“Psychedelics increase the neuroplasticity in your brain that we can measure. I could look at your brain before and after psychedelics. Before, it looks like an internet map of Africa — some areas don’t have connectivity. Afterward, it looks like an internet map of Europe, with condensed connections everywhere.”

YouTube

Spotify

Apple

Thank you to the partners who make this possible

Enterpret: Transform feedback chaos into actionable customer intelligence.

Auth0: Secure access for everyone. But not just anyone.

Persona: Trusted identity verification for any use case.


Often called the godfather of NYC tech, Kevin Ryan is one of America’s most influential entrepreneurs and investors. He co-founded MongoDB, Business Insider, Gilt Groupe, Zola, and Transcend Therapeutics, and continues to build and back new companies each year through AlleyCorp. Earlier in his career, he led DoubleClick from a 20-person startup to a global leader, taking it public before its acquisition by Google.

In this episode, Kevin shares his insights on two surprising pockets of the future that he’s betting on: psychedelics for mental health and AI-powered materials science. He unpacks how psychedelics are showing remarkable success in treating depression and PTSD, and why AI may discover revolutionary new materials, from helicopter blades to smartphone glass, that humans never imagined possible.

We explore:

  • The promising results of psychedelics in treating depression, PTSD, and addiction

  • How AI is accelerating materials discovery by exploring combinations humans wouldn’t try

  • The challenges of building successful incubators and why most attempts fail

  • How MongoDB lost $1 billion before turning a profit (and why it was worth it)

  • Why e-commerce businesses like Gilt Groupe often struggle against physical retail

  • How AlleyCorp plans for the future when shaping its investment strategy

  • What it really costs society to imprison someone for a year

  • The hard truth about Europe’s tech ecosystem and why it struggles to compete with the US


Explore the episode

Timestamps

(00:00) Intro

(04:30) How Kevin collaborated with Scott Adams

(07:11) The origins of AlleyCorp

(08:33) The challenge of incubation

(10:00) Why intellectual flexibility matters

(10:54) What made MongoDB a breakout success

(13:49) How shifting market dynamics hurt Gilt’s business

(16:22) What Kevin would do differently if he built Gilt again

(17:45) Juggling AlleyCorp’s long-term vision with day-to-day demands

(20:26) How to make boards more productive

(22:25) Why Kevin believes investors should also found companies

(24:18) Future spaces Kevin is excited to invest in

(25:52) Kevin’s interest in psychedelics and founding Transcend

(28:20) Psychedelics for mental health

(32:03) How psychedelic therapy is being conducted

(34:11) Transcend’s work and the path to approval for methylone

(37:47) The challenges of psychedelic research

(40:28) How the Trump administration aims to accelerate psychedelic research

(41:50) The size and growth of the psychedelic market

(44:28) Materials science: What it is, its design tradeoffs, and how AI speeds discovery

(49:02) Radical AI’s work creating new compounds

(50:34) The industries Radical AI is targeting

(52:50) The state of European tech and why it still lags behind

(58:26) Final meditations


Follow Kevin Ryan

LinkedIn: https://www.linkedin.com/in/kevinryan3/

X: https://x.com/alley_corp


Resources and episode mentions

Books

  • How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence: https://www.amazon.com/Change-Your-Mind-Consciousness-Transcendence/dp/1594204225

  • Breakneck: China’s Quest to Engineer the Future: https://www.amazon.com/Breakneck-Chinas-Quest-Engineer-Future/dp/1324106034

  • Why We Sleep: Unlocking the Power of Sleep and Dreams: https://www.amazon.com/Why-We-Sleep-Unlocking-Dreams/dp/1501144324

  • Outlive: The Science and Art of Longevity: https://www.amazon.com/Outlive-Longevity-Peter-Attia-MD/dp/0593236599

  • Birnam Wood: https://www.amazon.com/Birnam-Wood-Novel-Eleanor-Catton/dp/1250321719

  • The Odyssey: https://www.amazon.com/Odyssey-Homer/dp/0393356256

  • Invisible Man: https://www.amazon.com/Invisible-Man-Ralph-Ellison/dp/0679732764

  • Abundance: https://www.amazon.com/Abundance-Progress-Takes-Ezra-Klein/dp/1668023482

  • The Optimist: Sam Altman, OpenAI, and the Race to Invent the Future: https://www.amazon.com/Optimist-Altman-OpenAI-Invent-Future/dp/1324075961

  • The Gods of New York: Egotists, Idealists, Opportunists, and the Birth of the Modern City: 1986-1990: https://www.amazon.com/Gods-New-York-Idealists-Opportunists/dp/052551063X

People

  • Eliot Horowitz on LinkedIn: https://www.linkedin.com/in/eliothorowitz

  • Dwight Merriman on LinkedIn: https://www.linkedin.com/in/dmerr

  • Fred Wilson on LinkedIn: https://www.linkedin.com/in/fredwilson

  • Jamie Dimon on LinkedIn: https://www.linkedin.com/in/jamiedimon

  • Joseph F. Krause on LinkedIn: https://www.linkedin.com/in/josephfkrause

  • Jorge Colindres on LinkedIn: https://www.linkedin.com/in/jcolindres

  • James Baldwin: https://nmaahc.si.edu/explore/stories/introduction-james-baldwin

Other resources

  • Dilbert: https://dilbert.com

  • Peanuts: https://www.peanuts.com

  • DoubleClick: https://en.wikipedia.org/wiki/DoubleClick

  • MongoDB: https://www.mongodb.com

  • Business Insider: https://www.businessinsider.com

  • Zola: https://www.zola.com

  • Gilt Groupe: https://en.wikipedia.org/wiki/Gilt_Groupe

  • AlleyCorp: https://alleycorp.com

  • Oracle: https://www.oracle.com

  • SAP: https://www.sap.com

  • Snowflake: https://www.snowflake.com

  • John Deere: https://www.deere.com

  • Tech:NYC: https://www.technyc.org

  • Stepful: https://www.stepful.com

  • Yale Program for Psychedelic Science: https://medicine.yale.edu/psychiatry/research/clinics-and-programs/psychedelic/

  • Transcend: https://transcendtherapeutics.com/

  • A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1): https://clinicaltrials.gov/study/NCT03537014

  • Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study: https://pubmed.ncbi.nlm.nih.gov/28402682/

  • Methylone: https://www.sciencedirect.com/topics/medicine-and-dentistry/methylone

  • AlphaGo: https://deepmind.google/research/projects/alphago

  • Radical AI: https://www.radical-ai.com

  • Uala: https://www.uala.com.ar

  • Noma: https://noma.dk

  • Revolut: https://www.revolut.com

  • Monzo: https://monzo.com

  • Here’s What Happens When You Give People Free Money: https://www.wired.com/story/sam-altmans-big-basic-income-study-is-finally-out

  • Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy: https://pmc.ncbi.nlm.nih.gov/articles/PMC11378972/


Subscribe to the show

I’d love it if you’d subscribe and share the show. Your support makes all the difference as we try to bring more curious minds into the conversation.

YouTube

Spotify

Apple


Production and marketing by penname.co. For inquiries about sponsoring the podcast, email [email protected].

You're currently a free subscriber to The Generalist. For the full experience, upgrade your subscription.

Upgrade to paid

 
Like
Comment
Restack
 

© 2025 The Generalist LLC
228 Park Ave S PMB 19543, New York, New York 10003-1502 US
Unsubscribe

Get the appStart writing